...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model.
【24h】

DNA sequence capture and enrichment by microarray followed by next-generation sequencing for targeted resequencing: neurofibromatosis type 1 gene as a model.

机译:通过微阵列捕获和富集DNA序列,然后进行下一代测序以进行靶向重测序:将1型神经纤维瘤病基因作为模型。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The introduction and use of next-generation sequencing (NGS) techniques have taken genomic research into a new era; however, implementing such powerful techniques in diagnostics laboratories for applications such as resequencing of targeted disease genes requires attention to technical issues, including sequencing template enrichment, management of massive data, and high interference by homologous sequences. METHODS: In this study, we investigated a process for enriching DNA samples that uses a customized high-density oligonucleotide microarray to enrich a targeted 280-kb region of the NF1 (neurofibromin 1) gene. The captured DNA was sequenced with the Roche/454 GS FLX system. Two NF1 samples (CN1 and CN2) with known genotypes were tested with this protocol. RESULTS: Targeted microarray capture may also capture sequences from nontargeted regions in the genome. The capture specificity estimated for the targeted NF1 region was approximately 60%. The de novo Alu insertion was partially detected in sample CN1 by additional de novo assembly with 50% base-match stringency; the single-base deletion in sample CN2 was successfully detected by reference mapping. Interferences by pseudogene sequences were removed by means of dual-mode reference-mapping analysis, which reduced the risk of generating false-positive data. The risk of generating false-negative data was minimized with higher sequence coverage (>30x). CONCLUSIONS: We used a clinically relevant complex genomic target to evaluate a microarray-based sample-enrichment process and an NGS instrument for clinical resequencing purposes. The results allowed us to develop a systematic data-analysis strategy and algorithm to fit potential clinical applications.
机译:背景技术:下一代测序(NGS)技术的引入和使用已将基因组研究带入了一个新时代。但是,在诊断实验室中针对诸如靶向疾病基因的重测序之类的应用实施如此强大的技术,需要注意技术问题,包括测序模板的富集,海量数据的管理以及同源序列的高度干扰。方法:在这项研究中,我们调查了富集DNA样品的过程,该过程使用定制的高密度寡核苷酸微阵列来富集NF1(神经纤维蛋白1)基因的目标280 KB区域。用Roche / 454 GS FLX系统对捕获的DNA进行测序。使用此方案测试了两个具有已知基因型的NF1样品(CN1和CN2)。结果:靶向微阵列捕获也可能捕获基因组中非靶向区域的序列。估计的靶向NF1区域的捕获特异性约为60%。通过另外的具有50%碱基匹配严格性的从头组装,在样品CN1中部分检测到从头插入Alu。通过参考映射成功检测到样品CN2中的单碱基删除。伪基因序列的干扰通过双模式参考映射分析得以消除,从而降低了产生假阳性数据的风险。较高的序列覆盖率(> 30x)可将产生假阴性数据的风险降到最低。结论:我们使用了临床相关的复杂基因组靶标,评估了基于微阵列的样品富集过程和用于临床重测序目的的NGS仪器。结果使我们能够开发出系统的数据分析策略和算法,以适合潜在的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号